泰格医药遭投资反噬 国内业务断崖下跌暴露投资模式脆弱性|财报异动透视镜

华夏时报
23 Apr

百亿“赌局”崩盘!泰格医药净利润腰斩。  泰格医药(300347.SZ)2024年财报显示,公司营收与净利润双双大幅下滑,全年营收同比下降10.58%至66.03亿元,归母净利润骤降79.99%。这一表现主要受国内创新药研发需求萎缩、订单价格竞争加剧,以及非经常性损益项目的拖累。其中,金融资产公允价值变动成为净利润暴跌的主因,公司此前通过投资布局积累的“CRO+投资”模式,因市场波动导致资产价值...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10